Status:
ACTIVE_NOT_RECRUITING
A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Chronic Spontaneous Urticaria
Eligibility:
All Genders
18-80 years
Brief Summary
This is a multicenter, non-randomized, non-interventional two-cohort study with prospective collection of primary data on monitoring of Chronic spontaneous urticaria (CSU) patients by telemedicine or ...
Detailed Description
This study will investigate the effect of digital monitoring via teledermatology on patient-reported outcomes (PRO) usage in CSU. The automatic provision of PROs at each digital patient-physician cont...
Eligibility Criteria
Inclusion
- Adults aged 18 and above
- Written informed consent for participation obtained from the subject
- Diagnosed chronic spontaneous urticaria
- Medical therapy for CSU
- Concomitant chronic inducible urticaria is allowed
- Willing and be able to perform digital visits
Exclusion
- • Simultaneous participation in any clinical trial
Key Trial Info
Start Date :
June 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT06991608
Start Date
June 11 2024
End Date
December 31 2025
Last Update
July 16 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Hamburg, Hamburg, Germany, 22391
2
Novartis Investigative Site
Lingen Ems, Lower Saxony, Germany, 49809
3
Novartis Investigative Site
Koblenz, Rhineland-Palatinate, Germany, 56068
4
Novartis Investigative Site
Leipzig, Saxony, Germany, 04103